Gatifloxacin pulled from last major market
This article was originally published in Scrip
Kyorin Pharmaceuticaland Dainippon Sumitomo Pharma(DSP) have voluntarily discontinued all sales of the antibacterial Gatiflo (gatifloxacin) in Japan. The decision was prompted by continued reports of abnormal blood glucose levels during the use of the oral fluoroquinolone, which the firms said could not be disassociated from its use.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.